Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification

N Schwab, T Schneider-Hohendorf, N Melzer… - Neurology, 2017 - AAN Enterprises
Progressive multifocal leukoencephalopathy (PML) associated with natalizumab treatment
continues to be a severe problem of clinically successful therapy. This is an update of risk …

[HTML][HTML] Adverse psychiatric effects of disease-modifying therapies in multiple sclerosis: a systematic review

M Gasim, CN Bernstein, LA Graff, SB Patten… - Multiple sclerosis and …, 2018 - Elsevier
Background Psychiatric comorbidity is prevalent in persons with multiple sclerosis (MS). Few
studies have assessed whether second-generation disease-modifying therapies (DMT) are …

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis

B Turner, BAC Cree, L Kappos, X Montalban… - Journal of …, 2019 - Springer
Objective The efficacy and safety of ocrelizumab, versus interferon (IFN) β-1a, for the
treatment of relapsing multiple sclerosis (RMS) from the identically designed OPERA I …

Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases

RP Maas, AHG Muller-Hansma, RAJ Esselink… - Journal of …, 2016 - Springer
The implementation of a variety of immunosuppressive therapies has made drug-associated
progressive multifocal leukoencephalopathy (PML) an increasingly prevalent clinical entity …

Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis

LV Rindi, D Zaçe, N Braccialarghe, B Massa, V Barchi… - Drug Safety, 2024 - Springer
Introduction Progressive multifocal leukoencephalopathy (PML) was first described among
patients affected by hematological or solid tumors. Following the human immunodeficiency …

Immunosuppressive agents for the treatment of primary sclerosing cholangitis: a systematic review and meta-analysis

X Peng, X Luo, JY Hou, SY Wu, LZ Li, MH Zheng… - Digestive …, 2017 - karger.com
Objectives: Currently, there are no effective therapeutic agents for patients with primary
sclerosing cholangitis (PSC). This study aimed to evaluate the safety and efficiency of …

Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis

BAC Cree, JA Cohen, AT Reder… - Multiple Sclerosis …, 2021 - journals.sagepub.com
Background: Disease-modifying therapies (DMTs) can reduce the risk of disability
worsening in patients with relapsing forms of multiple sclerosis (RMS). High-efficacy DMTs …

Use of natalizumab in multiple sclerosis: current perspectives

S Gandhi, D Jakimovski, R Ahmed… - Expert Opinion on …, 2016 - Taylor & Francis
Introduction: Natalizumab is an efficacious monoclonal antibody approved for use in
relapsing-remitting multiple sclerosis (RRMS). Multiple studies have demonstrated reduced …

Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis?

JI Rojas, A Pappolla, L Patrucco, E Cristiano… - Multiple Sclerosis and …, 2020 - Elsevier
We often see that clinical and demographic characteristics of real-world studies (RWS) do
not differ from patients included in randomized controlled trials (RCT). Objective: to compare …

Natalizumab in relapsing-remitting multiple sclerosis

O Outteryck - Expert Review of Neurotherapeutics, 2016 - Taylor & Francis
Natalizumab is the first humanized moclonal antibody indicated in the treatment of relapsing-
remitting multiple sclerosis (RRMS). Based on its remarkable efficacy in reducing disease …